Semaglutide vs Tirzepatide
Comparing the two most potent GLP-1 receptor agonists in modern metabolic research. Understanding the differences in molecular structure, stability, and clinical outcomes.
| Feature | Semaglutide (Ozempic/Wegovy) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Mechanism | Selective GLP-1 Receptor Agonist | Dual GLP-1 and GIP Receptor Agonist |
| Molecular Stability | Robust (Highly stable in solution) | Standard (Slightly more sensitive) |
| Fridge Life | Up to 56 days | Up to 30 days |
| Clinical Weight Loss | ~14.9% (STEP trials) | ~20.9% (SURMOUNT trials) |
| Typical Frequency | Once Weekly | Once Weekly |
Key Differences for Researchers
While both peptides target the GLP-1 receptor, Tirzepatide is unique because it also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual-action approach has demonstrated superior weight loss and glycemic control in head-to-head clinical trials.
From a stability perspective, Semaglutide is generally more robust once reconstituted. Our data indicates that Semaglutide maintains potency significantly longer at various temperatures compared to Tirzepatide, which is slightly more susceptible to environmental degradation.